TY - JOUR
T1 - Risk of Cardiovascular Events After COVID-19
AU - Tereshchenko, Larisa G.
AU - Bishop, Adam
AU - Fisher-Campbell, Nora
AU - Levene, Jacqueline
AU - Morris, Craig C.
AU - Patel, Hetal
AU - Beeson, Erynn
AU - Blank, Jessica A.
AU - Bradner, JG N.
AU - Coblens, Michelle
AU - Corpron, Jacob W.
AU - Davison, Jenna M.
AU - Denny, Kathleen
AU - Earp, Mary S.
AU - Florea, Simeon
AU - Freeman, Howard
AU - Fuson, Olivia
AU - Guillot, Florian H.
AU - Haq, Kazi T.
AU - Kim, Morris
AU - Kolseth, Clinton
AU - Krol, Olivia
AU - Lin, Lisa
AU - Litwin, Liat
AU - Malik, Aneeq
AU - Mitchell, Evan
AU - Mohapatra, Aman
AU - Mullen, Cassandra
AU - Nix, Chad D.
AU - Oyeyemi, Ayodele
AU - Rutlen, Christine
AU - Tam, Ashley E.
AU - Van Buren, Inga
AU - Wallace, Jessica
AU - Khan, Akram
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/9/15
Y1 - 2022/9/15
N2 - We aimed to determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular (CV) events and all-cause mortality. We conducted a retrospective double cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection (COVID-19+ cohort) and its documented absence (COVID-19− cohort). The study investigators drew a simple random sample of records from all patients under the Oregon Health & Science University Healthcare (n = 65,585), with available COVID-19 test results, performed March 1, 2020 to September 13, 2020. Exclusion criteria were age <18 years and no established Oregon Health & Science University care. The primary outcome was a composite of CV morbidity and mortality. All-cause mortality was the secondary outcome. The study population included 1,355 patients (mean age 48.7 ± 20.5 years; 770 women [57%], 977 White non-Hispanic [72%]; 1,072 ensured [79%]; 563 with CV disease history [42%]). During a median 6 months at risk, the primary composite outcome was observed in 38 of 319 patients who were COVID-19+ (12%) and 65 of 1,036 patients who were COVID-19− (6%). In the Cox regression, adjusted for demographics, health insurance, and reason for COVID-19 testing, SARS-CoV-2 infection was associated with the risk for primary composite outcome (hazard ratio 1.71, 95% confidence interval 1.06 to 2.78, p = 0.029). Inverse probability-weighted estimation, conditioned for 31 covariates, showed that for every patient who was COVID-19+, the average time to all-cause death was 65.5 days less than when all these patients were COVID-19−: average treatment effect on the treated −65.5 (95% confidence interval −125.4 to −5.61) days, p = 0.032. In conclusion, either symptomatic or asymptomatic SARS-CoV-2 infection is associated with an increased risk for late CV outcomes and has a causal effect on all-cause mortality in a late post-COVID-19 period.
AB - We aimed to determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular (CV) events and all-cause mortality. We conducted a retrospective double cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection (COVID-19+ cohort) and its documented absence (COVID-19− cohort). The study investigators drew a simple random sample of records from all patients under the Oregon Health & Science University Healthcare (n = 65,585), with available COVID-19 test results, performed March 1, 2020 to September 13, 2020. Exclusion criteria were age <18 years and no established Oregon Health & Science University care. The primary outcome was a composite of CV morbidity and mortality. All-cause mortality was the secondary outcome. The study population included 1,355 patients (mean age 48.7 ± 20.5 years; 770 women [57%], 977 White non-Hispanic [72%]; 1,072 ensured [79%]; 563 with CV disease history [42%]). During a median 6 months at risk, the primary composite outcome was observed in 38 of 319 patients who were COVID-19+ (12%) and 65 of 1,036 patients who were COVID-19− (6%). In the Cox regression, adjusted for demographics, health insurance, and reason for COVID-19 testing, SARS-CoV-2 infection was associated with the risk for primary composite outcome (hazard ratio 1.71, 95% confidence interval 1.06 to 2.78, p = 0.029). Inverse probability-weighted estimation, conditioned for 31 covariates, showed that for every patient who was COVID-19+, the average time to all-cause death was 65.5 days less than when all these patients were COVID-19−: average treatment effect on the treated −65.5 (95% confidence interval −125.4 to −5.61) days, p = 0.032. In conclusion, either symptomatic or asymptomatic SARS-CoV-2 infection is associated with an increased risk for late CV outcomes and has a causal effect on all-cause mortality in a late post-COVID-19 period.
UR - http://www.scopus.com/inward/record.url?scp=85134756456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134756456&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2022.06.023
DO - 10.1016/j.amjcard.2022.06.023
M3 - Article
C2 - 35843735
AN - SCOPUS:85134756456
SN - 0002-9149
VL - 179
SP - 102
EP - 109
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -